Ischemia/reperfusion (I/R) injury has been identified as a major stress for cellular death in several disease states, including myocardial infarction [1] . I/R causes tissue injury as a result of both apoptosis and necrosis [2] . Although the mechanism of cardiomyocyte cell death is currently the subject of intensive investigation, a detailed study of signaling pathways leading to myocardial cell death following I/R has yet to be performed.
A brief episode of ischemia renders the heart more tolerant to a subsequent prolonged ischemic injury, an effect known as preconditioning [3, 4] . ATP-sensitive potassium channel (K ATP ) has been suggested to serve as an endogenous cardioprotector because preconditioning is thought to be mediated by an activation of K ATP channels [5] . Although cromakalim was discovered as a K ATP channel activator, it opens K ATP channels also under nonischemic conditions [6] . In this regard, BMS-180448 ([3S-trans]-N- [4-chlorophenyl] -N ′-cyano-N ″-[6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl] guanidine) was the first compound to demonstrate selective K ATP channel-opening activity under hypoxic conditions [7] . However, since cromakalim and BMS-180448 have vasodilator activity, the need for a cardioselective K ATP channel activator without this activity remained, prompting the development of KR-31378.
A novel benzopyran derivative, KR-31378 ([2S,3S,4R]-N″-cyano-N-[6-amino-3,4-dihydro-3-hydroxy-2-methoxymethyl-2H-benzopyran-4-yl]-N′-benzylguanidine) (Fig. 1) , was synthesized by the Korea Research Institute of Chemical Technology (Daejeon, Korea) as a chemical preconditioning agent [8] . KR-31378 is an antioxidant K ATP channel opener that has been shown to protect rat cortex neurons against iron-induced oxidative injury, and it significantly reduces infarct size in a model of rat transient cerebral ischemia [9] [10] [11] . KR-31378 is a potent reactive oxygen species (ROS) scavenging agent and demonstrates an antiapoptotic effect in smooth muscle cells [12] . Recently, KR-31378 was reported to act as a potential inhibitor against atherosclerosis in a mouse model [13] . KR-31378 ameliorates atherosclerosis by inhibiting NF-κB-dependent cellular adhesion and the expression of chemotactic molecules such as the cell adhesion molecule and interleukin-8. The above-mentioned KR-31378 studies were performed in a cerebral ischemic model and endothelial cells, making the present study the first report to examine the protective effect of KR-31378 in heart-derived H9c2 cells. Fig. 1) , KR-31981 (1-methyl-5-nitroisatin), KR-31982 (1-benyl-5-nitroisatin) [15] , and BMS-180448 were synthesized and dissolved in dimethyl sulfoxide as 100 mM stock solutions. SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), was obtained from TOCRIS (Ellisville, MO, USA). SB203580 (a highly specific inhibitor of p38 MAP kinase), U0126 (an inhibitor of MEK1), and z-Val-Ala-Asp (Ome)-CH 2 F (zVAD-fmk, a pan caspase inhibitor) were purchased from Calbiochem (La Jolla, CA, USA). α-Tocopherol was obtained from Sigma (Sigma, St. Louis, MO, USA).
METHODS

Chemicals and reagents. KR-31378 (
Cell culture. Rat heart-derived H9c2 cells were cultured in Dulbeco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 1% antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin [Gibco-BRL, Gaithersburg, MD, USA]). The cells were subcultured after trypsinization with a solution of trypsin-EDTA. They were grown to confluency at 37°C in the presence of 95% air and 5% CO 2 in culture dishes.
Metabolic inhibition model. The cells were washed once with phosphate-buffered saline (PBS) before an addition of metabolic inhibition buffer (106 mM NaCl, 4.4 mM KCl, 1 mM MgCl 2 · 6H 2 O, 38 mM NaHCO 3 , 2.5 mM CaCl 2 , 20 mM 2-deoxy-D-glucose, 1 mM NaCN, pH 6.6) [16] and placed in the metabolic inhibition buffer for indicated times (Fig. 2) .
Measurement of cell viability and lactate dehydrogenase (LDH) release. We have previously shown that chemical hypoxia (CH) induces myocardial cell death through the protein kinase C ε (PKCε)-JNK/p38 MAPK signaling pathway [14] . CH-induced cell death occurred in a caspase-independent manner. c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) were activated, and extracellular signal-regulated kinase (ERK) and caspases were inactivated under conditions of chemical hypoxia. Thus the present study examined if KR-31378's protective effect came from modulating MAPK activity and/or caspase activity. Our data show that KR-31378's cardioprotective effect is due, at least in part, to its ability to inhibit the JNK/p38 MAPK activation in CH-induced cell death. A cell-based caspase assay was performed by a modification of the manufacturer's protocols (Peptron). Briefly, 1 × 10 5 cells were harvested and resuspended in 50 µl lysis buffer. All enzymatic reactions were carried out at 37°C for 30 min in reaction buffer containing 50 µM Ac-DEVD-AMC. The release of fluorescent AMC was measured with Perkin-Elmer LS-50B luminescence spectrometer (Perkin Elmer Life and Analytical Sciences, Boston, MA, USA) at excitation and emission wavelengths, 360 nm and 460 nm, respectively.
Flow cytometric analysis. The quantification of CH-induced cell death by fluorescence-activated cell sorting (FACS) analysis was performed as follows. The cells were treated with metabolic inhibition buffer in the presence or absence of KR-31378 for the indicated concentration. At the end of the treatment, they were detached with trypsin-EDTA, pelleted by centrifugation, and washed with PBS. Immediately before FACS analysis, the samples were incubated with DNase-free RNase for 30 min at 37°C. Propidium iodide (PI, 50 µg/ml) and annexin V-fluorescein isothiocyanate (FITC) were added, and FACS analysis was performed with a Beckmann EPICS flow.
MAPK phosphorylation assay. To measure MAPK activity, we washed the cells twice in 1× PBS and immediately lysed in the mammalian lysis buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.4 mM phenylmethylsulfonyl fluoride) and sonicated. After sonication, the cells were centrifuged at 13,000 × g and cell debris was removed. Cell extract proteins were incubated at 30°C for 30 min in kinase buffer (20 mM MOPS, 2 mM EGTA, 10 mM MgCl 2 , 1 mM DTT, 0.1% Triton X-100, 0.1 mM Na 3 VO 4 , 15 µM ATP, 10 µCi [γ-32 P]ATP) and the substrates (GST-c-Jun for JNK, GST-ATF-2 for p38 MAPK). SDS-sample buffer was added, and proteins were eluted from the beads by boiling for 5 min. After centrifugation, the supernatants were separated on SDS-PAGE. Phosphorylations of substrates were detected by autoradiography. Activations of ERK1/2 were determined by immunoblot. We used antiphospho-ERK1/2 antibody (Cell Signaling Technology, Beverly, MA, USA) to determine the activations of ERK 1/2 by immunoblot. Measuring intracellular ROS. The level of intracellular ROS was measured after CH with or without drugs (KR-31378, BMS-180448, and α-tocopherol) treatment. The measurement of intracellular ROS was based on a ROS-mediated conversion of 2′,7′-dichlorofluorescein diacetate (DCFH-DA) (Molecular Probes Inc., Eugene, OR, USA) into DCFH. DCFH-DA fluoresces green when oxidized. The cells were incubated for 30 min at 37°C in 50 mM phosphate buffer, pH 7.4, containing 5 µM DCFH-DA. We measured the quantity of fluorescence at an excitation wavelength of 485 nm and an emission wavelength of 530 nm by using Wallac 1420 Victor Multilable Counter (Perkin Elmer Life and Analytical Sciences). The fluorescence was detected by a BioRad Radiance 2000 confocal laser scanning microscope (BioRad, Richmond, CA, USA).
Statistical analysis. The data were expressed as mean ± SEM. Comparisons between groups of data were analyzed by a Student's t-test. Data analysis and graph generation were performed with Sigmaplot 8.0 (SPSS, Chicago, IL, USA). A value of P < 0.05 was accepted as statistically significant.
RESULTS
Effect of KR-31378 on cell viability. In the present study, we examined the cell viability and death of H9c2 cells after 2 h of CH using XTT assay and LDH assay, respectively. In H9c2 cells exposed to CH for 2 h, cell viability was markedly reduced, and cell death was gradually increased. The decrease in cell viability was inhibited by treatment with KR-31378 (1-20 µM) in a concentration-dependent manner (Fig.  3, upper panel) . After the application of KR-31378 (20 µM), the cells showed 65.3 ± 3.1% viability when compared to the untreated cells. Similarly, the LDH release was inhibited and decreased from 56.4 ± 2.4 (vehicle treated) to 25.9 ± 1.2% (20 µM, KR-31378) (Fig. 3) through a concentration-dependent treatment of KR-31378 (1-20 µM). BMS-180448 behaved in a similar fashion, but it was less potent than KR-31378 in cardioprotection. H9c2 cells were exposed to CH in the presence of KR-31378 and BMS-180448, respectively. KR-31378 and BMS-180448 were added 2 h before and during CH. XTT assay was performed as described under "METHODS." Results were normalized to 100% for untreated cells. LDH activity was measured from the medium as described under "METHODS." LDH release was normalized from the maximum LDH release induced by 0.1% Triton X-100. Ctrl, untreated; Veh, vehicle treated. *P < 0.05 vs. Veh.
KR-31378 acts independent of the caspase cascade.
In this study, we tested whether the protective signaling pathway of KR-31378 was mediated through the caspase cascade. The specific inhibitors of caspase-3, KR-31981, and KR-31982, were used as controls for a caspase-3 activity assay [15] . In our previous report, we demonstrated that CH decreased the activity of caspase-3, caspase-8, and caspase-9 [14] . As shown in Fig. 4 , caspase-3 activity was not affected by KR-31378 in vitro (Fig. 4, upper panel) . This lack of change in caspase-3 activity in H9c2 cells indicates that KR-31378 acts independently of the caspase cascade (Fig. 4, lower panel) . 
Fig. 4. KR-31378 does not affect caspase activities. In vitro caspase-3 activity assay was performed as described in "METHODS" (upper panel). The specific inhibitors of caspase-3, KR-31981 (1-methyl-5-nitroisatin), and KR-31982
(1-benyl-5-nitroisatin) were used as controls for a caspase-3 activity assay. Rat heart derived H9c2 cells cultured in 60 mm plates were left in DMEM medium followed by CH treatment 2 h before the analysis for fluorometric caspase-3 assay (lower panel). KR-31378 was added 2 h before and during CH. Ctrl, untreated; Veh, vehicle treated. *P < 0.05 vs. Ctrl.
Characterization of CH-induced H9c2 cell death.
We performed a FACS analysis to characterize the protective mechanism of KR-31378. Rat heart derived H9c2 cells showed an increase of propidium iodide (PI) staining after CH, indicating the rapid onset of necrosis, and the increased cell population stained annexin V negative, excluding the possibility of apoptosis (Fig. 5) . This method allows differentiation between apoptotic (annexin V positive, PI negative) and necrotic (annexin V negative, PI positive) cells. The amount of necrotic cells was decreased from 89.6 ± 1 (vehicle treated) to 17.4 ± 0.8% by the treatment with 20 µM of KR-31378 (Fig. 5) . However, the number of necrotic cells was not significantly affected by treatment with zVAD-fmk, a pan caspase inhibitor. The failure of cardioprotection by zVADfmk treatment implies that caspases are not essential for the CH-induced cell death of H9c2 cells.
Inhibition of CH-induced JNK/p38 MAPK activation by KR-31378 in H9c2 cells.
Several reports have shown that the activation of MAPKs is responsible for apoptosis [17, 18] . In our previous report [14] , we revealed causal relationship between CH-induced JNK/p38 MAPK activation and myocardial cell death. To investigate whether KR-31378 inhibits CH-induced JNK/p38 MAPK activation and cell death, H9c2 cells were incubated with KR-31378 30 min before and during the CH treatment. Figure 6 shows that CH treatment significantly induced the activation of JNK and p38 MAPK and that activation levels dropped dramatically upon treatment with KR-31378. In contrast, KR-31378 did not prevent the dephosphorylation of ERK1/2 in response to CH. The quantitative analysis of MAPK activities was performed by densitometry (Fig. 6B) .
Cardioprotection by KR-31378 KR-31378 (10 µM) and SP600125 (10 µM) downregulated JNK activity to 0.77- (Fig. 6B ) and 1.53-fold (Fig. 7A) , respectively, when compared to untreated cells upon CH. IC 50 of KR-31378 in the suppression of CH-induced JNK activity in cardiomyocytes is 3.5 µM, which is comparable to the SP600125's IC 50 of 5-10 µM for the PMA-induced JNK activity suppression in Jurkat T cells [19] . KR-31378 was also more effective than SB203580 in p38 MAPK inhibition. Upon CH, KR-31378 (10 µM), and SB203580 (10 µM) downregulated p38 MAPK activity to 0.75 (Fig. 6B ) and 1.08-fold (Fig. 7B) , respectively, compared to the activity of untreated cells. Even though KR-31378 was more effective in MAPK suppression than SP600125 and SB203580, protective efficacies against cardiomyocyte death by KR-31378 and MAPK inhibitors were relatively similar because 10 µM of SP600125, SB203580, and KR-31378 increased the cell viability to 1.43-, 1.49-, and 1.55-fold of the untreated control, respectively.
KR-31378 inhibits chemical hypoxiainduced ROS formation. To determine whether KR-31378 suppresses the increase of intracellular ROS levels by CH, we assessed the effect of KR-31378 on ROS generation during CH. ROS was detected with DCFH-DA, which becomes highly fluorescent dichlorofluorescein (DCF) when oxidized by ROS. The exposure of H9c2 cells to 1 h of CH increased DCF fluorescence (Fig. 8A) . KR-31378-treated cells (10 µM) showed 58.1 ± 6.2% of DCF intensity when compared to the vehicle-treated cells, indicating that KR-31378 blocked CH-induced ROS generation. BMS-180448, a benzopyran analog (10 µM), also prevented ROS formation during CH (70.5 ± 2.1% of DCF intensity compared to vehicle-treated cells). KR-31378 was better in scavenging ROS than BMS-180448. KR-31378 demonstrated protective effects in HUVECs by decreasing intracellular ROS levels [12] . In this study, treatment with 10 µM KR-31378 also inhibited the CH-induced intracellular ROS rise in H9c2 cells (Fig. 8B) . α-tocopherol was used as a positive control for ROS scavenging. The result implies that KR-31378-mediated protection from CH-induced cell death might be related to the inhibition of ROS formation. 
DISCUSSION
The aim of this study was to examine the mechanism of KR-31378, a benzopyran analog, in cell survival against CH in H9c2 cells derived from rat hearts. The cardioprotective effect of KR-31378 is associated with the inhibition of JNK/p38 MAPK activation. However, KR-31378 restored neither the inactivated ERK1/2 activities nor the downregulated caspase activities in CH. Collectively, our data demonstrate that the cardioprotection of KR-31378 occurs via differential modulation of MAPKs in a caspase-independent manner. Even though JNK and p38 MAPK activity returns to below the control level with 10 µM KR-31378 treatment, protection from ischemic cell death was not complete (56.1 ± 1.0% of control). A failure of complete protection of ischemic H9c2 cells by the inhibition of JNK and p38 MAPK activations suggests the presence of JNK/p38 MAPK independent ischemic death pathways. ERK activity restoration might act as a complement to provide complete protection, since ERK activity is required for survival signaling in response to growth factors in L929 cells and PC12 cells and for protection against I/R-induced cardiomyocytic cell death [20] [21] [22] . It is conceivable that a combination of JNK/p38 MAPK and ERK activities might determine the extent of cardiomyocyte survival.
CH certainly displays characteristics of cell death different from those of apoptosis. Typical apoptotic phenomena such as caspase activation and phosphatidyl serine translocation in the cell membrane were not observed in CH-induced cell death (Fig. 5) . The transient ATP depletion of cells converts an apoptotic death signal to a necrotic one [23] . In our ischemic model, therefore, the failure of caspase activation might be caused by the depletion of ATP, a component of apoptosome. Thus at least for CH-induced cell death in H9c2 cells, the caspase-independent MAPK signaling module appears to play an important role.
Several benzopyran K ATP channel activators such as diazoxide, cromakalim, and BMS-180448 selectively open the MitoK ATP channel and demonstrate a cardioprotective effect against I/R, suggesting the MitoK ATP channel as a target molecule of cardioprotection [24] [25] [26] . And ROS plays an important role both upstream and downstream of the MitoK ATP channel during ischemia [27] . In the previous report, KR-31378 reduced the myocardial infarct zone to an area at risk in the ischemic myocardium rat model [8] . 5-Hydroxydecaoate (5-HD), a blocker of MitoK ATP channel, abolished the cardioprotective effect by KR-31378, suggesting that KR31378 acted through MitoK ATP channel [8] . This study further examined whether KR-31378 modulated ROS generation and demonstrated that CH-induced ROS formation was prevented by KR-31378 in H9c2 cells.
In the previous report, we newly identified the PKCε → JNK/p38 MAPK signaling module [14] . Since the phosphorylations during CH are blocked by KR-31378, it would be interesting to see if KR-31378 could also modulate PKCε activation. Moreover, KR-31378 prevents ROS generation induced by CH. Thus the disclosure of the relationships among the ROS generation, PKCε, and JNK/p38 MAPK activations would help us to understand the molecular mechanism underlying CH-induced cardiac cell death.
In conclusion, we have demonstrated that KR-31378 acts as a protective agent against CH in cardiomyocytes. This protection is associated with the differential regulation of MAPKs. This study has implications not only for a better understanding of signal pathways in CH-induced cardiomyocyte death, but also for the clinical application of KR-31378 as a cardioprotective agent.
